Public Policy Committee
Michael Sherman, M.D.
Senior Vice President, Chief Medical Officer, Harvard
Director, Federal Affairs and Policy, Bristol-Myers
PMC's Public Policy Committee collaborates to align policy priorities among PMC members and leverage relationships with policymakers to advance legislation and regulations that promote investment in and adoption of personalized medicine. The committee maintains two standing working groups comprised of patient advocates and industry stakeholders.
» Public Policy
Patient Advocate Organization Working Group
PMC's Patient Advocate Organization Working Group provides a forum for the Coalition's patient advocacy organization members to inform PMC’s policy strategy, align on legislative priorities, and develop shared messages that can empower individual patients to advocate for policies that bring personalized medicine closer to them.
Pharmaceutical & Diagnostics Working Group
PMC’s Pharmaceutical & Diagnostics Working Group provides a forum for the Coalition's pharmaceutical and diagnostic industry members to inform PMC’s policy strategy and advocacy activities related to research and development, regulatory oversight, reimbursement, payment reform, and health care quality.